4//SEC Filing
Struthers Richard Scott 4
Accession 0000950170-24-057926
CIK 0001658247other
Filed
May 9, 8:00 PM ET
Accepted
May 10, 4:57 PM ET
Size
12.3 KB
Accession
0000950170-24-057926
Insider Transaction Report
Form 4
Struthers Richard Scott
DirectorPresident & CEO
Transactions
- Exercise/Conversion
Common Stock
2024-05-08$9.28/sh+107,448$997,117→ 364,933 total - Sale
Common Stock
2024-05-08$49.40/sh−107,448$5,307,931→ 257,485 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-05-08−107,448→ 16,342 totalExercise: $9.28Exp: 2028-05-24→ Common Stock (107,448 underlying)
Holdings
- 570,805(indirect: By Trust)
Common Stock
- 110,000(indirect: By Trust)
Common Stock
- 110,000(indirect: By Trust)
Common Stock
- 110,000(indirect: By Trust)
Common Stock
- 1,000(indirect: By Spouse)
Common Stock
Footnotes (3)
- [F1]The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan entered into in March 2023.
- [F2]The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $49.40 per share. The range of sales prices on the transaction date was $48.95 to $50.15 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
- [F3]1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Documents
Issuer
Crinetics Pharmaceuticals, Inc.
CIK 0001658247
Entity typeother
Related Parties
1- filerCIK 0001746298
Filing Metadata
- Form type
- 4
- Filed
- May 9, 8:00 PM ET
- Accepted
- May 10, 4:57 PM ET
- Size
- 12.3 KB